mehtaconstructionshyd.com → stock → company stock supply → what pharmaceutical company makes eliquis
Posted on by Oakley Murray

What Pharmaceutical Company Makes Eliquis

White capsule labeled 'Eliquis' on a clean lab surface with medical equipment in background

Eliquis is a blood thinner medication developed and marketed by Bristol-Myers Squibb and Pfizer under a joint agreement. The drug contains apixaban, a direct oral anticoagulant used to prevent strokes in patients with atrial fibrillation and to treat or prevent deep vein thrombosis and pulmonary embolism.

Apixaban was discovered through research at Pfizer's global drug discovery center in Groton, Connecticut. The compound entered clinical trials in 2006. Bristol-Myers Squibb joined the development effort in 2008 after acquiring rights to further develop and commercialize the molecule. The two companies formed a collaboration to bring Eliquis to market, sharing responsibilities for clinical development, regulatory approval, and sales.

The U.S. Food and Drug Administration approved Eliquis in December 2012 for the prevention of stroke in non-valvular atrial fibrillation. Approval expanded in 2014 to include treatment of deep vein thrombosis and pulmonary embolism. By 2020, Eliquis had generated over $2 billion in annual sales in the United States alone, making it one of the most prescribed anticoagulants in the country.

How Eliquis Works

Eliquis works by inhibiting factor Xa, a key protein in the blood clotting cascade. Unlike warfarin, which requires frequent blood monitoring and dietary restrictions, Eliquis does not require routine INR testing. Patients take one 5 mg tablet twice daily, with or without food.

A 2018 study published in the New England Journal of Medicine compared Eliquis to warfarin in over 18,000 patients with non-valvular atrial fibrillation. The trial showed a 21% lower risk of stroke or systemic embolism and a 31% reduction in major bleeding events with Eliquis. These results contributed to its widespread adoption among cardiologists and primary care providers.

Patients with moderate renal impairment (creatinine clearance 30-50 mL/min) are advised to reduce the dose to 2.5 mg twice daily. Those with severe impairment (below 30 mL/min) should not use Eliquis due to increased risk of bleeding and reduced drug clearance.

Types of Anticoagulants and How Eliquis Fits In

Anticoagulants fall into two main categories: vitamin K antagonists (like warfarin) and direct oral anticoagulants (DOACs). Eliquis belongs to the DOAC class, which includes rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa).

Drug Active Ingredient Target Dosing Frequency Renal Dose Adjustment Needed?
Eliquis Apixaban Factor Xa Twice daily Yes (for CrCl 30-50)
Xarelto Rivaroxaban Factor Xa Once daily Yes (for CrCl <30)
Pradaxa Dabigatran Thrombin Twice daily Yes (for CrCl <30)
Savaysa Edoxaban Factor Xa Once daily Yes (for CrCl <15)

Unlike warfarin, which acts on multiple clotting factors and interacts with many foods and drugs, apixaban targets only factor Xa. This specificity reduces the risk of unpredictable bleeding and drug interactions. A 2021 analysis from the American Heart Association noted that DOACs like Eliquis have lower rates of intracranial hemorrhage compared to warfarin, especially in older adults.

Common Misconceptions About Eliquis

Many patients assume Eliquis is a "newer" drug because it replaced warfarin in many guidelines. But apixaban was first synthesized in 2000 and underwent clinical testing over a decade before approval. The drug was not rushed to market-it went through rigorous Phase II and III trials involving tens of thousands of participants.

Another misconception is that Eliquis is only for stroke prevention. While it's widely used for atrial fibrillation, it's also approved for treating existing clots and preventing recurrence. In orthopedic surgery, such as hip or knee replacement, Eliquis reduces the risk of venous thromboembolism by 60% compared to placebo, according to a 2014 trial published in JAMA Internal Medicine.

Some patients also believe they can stop taking Eliquis abruptly if they experience minor bruising. That's incorrect. Stopping anticoagulants without medical supervision increases the risk of clot formation. The FDA warns against discontinuing Eliquis without consulting a healthcare provider, even for mild side effects.

Real-World Example: A Patient's Experience

In 2019, a 68-year-old man with non-valvular atrial fibrillation began taking Eliquis after his doctor switched him from warfarin. He had experienced two episodes of uncontrolled bleeding while on warfarin, requiring emergency visits. After switching to Eliquis, he reported no bleeding events over the next 18 months. His INR levels were stable, and he didn't need monthly blood draws.

His physician noted that Eliquis improved adherence-patients were more likely to take their medication consistently when not tied to regular lab tests. The patient's quality of life improved, allowing him to travel and return to light physical activities without fear of clot-related complications.

Why the Joint Development Matters

Bristol-Myers Squibb and Pfizer share development costs and profits from Eliquis. They jointly fund ongoing safety monitoring and post-marketing studies. This partnership allows both companies to pool resources and expertise, reducing financial risk and accelerating access to new data.

As of 2023, the companies continue to conduct long-term follow-up studies on Eliquis' cardiovascular outcomes. One such study, the ARISTOTLE trial extension, tracked over 17,000 patients for five years. Results confirmed sustained benefits in stroke prevention and lower mortality compared to warfarin, reinforcing Eliquis' role in modern cardiology.

Despite being co-developed, Bristol-Myers Squibb holds marketing rights in the U.S., while Pfizer manages distribution and marketing in Europe and parts of Asia. This division of labor reflects a common model in pharmaceutical partnerships, where one partner leads in certain regions based on infrastructure and regulatory relationships.

Final Answer: What Pharmaceutical Company Makes Eliquis?

The pharmaceutical company that makes Eliquis is Bristol-Myers Squibb, in collaboration with Pfizer. Both companies jointly developed and commercialize the drug under a shared agreement. Eliquis is manufactured at facilities owned by Bristol-Myers Squibb in New Jersey and distributed globally through established pharmaceutical supply chains.


Related Posts